HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target
Benzinga Newsdesk 5 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Tyra Biosciences (NASDAQ:TYRA) with a Buy and maintains $45 price target.